Table 2.

Associations of nominally significant vitamin D pathway SNPS and lethal prostate cancer stratified by high vs. low 25(OH)D

Gene: SNP (Major/Minor allele)	OR* and 95% CI for low 25(OH)D strata	p-value	OR* and 95% CI for high 25(OH)D strata	p-value	p-interaction#
VDR:rs2239186(A,G)	1.26(0.88-1.78)	0.20	1.44(1.01-2.05)	0.04	0.44
VDR:rs2189480(G,T)	1.44(1.05-1.97)	0.02	1.12(0.83-1.50)	0.47	0.60
VDR:rs2283342(A,G)	1.07(0.72-1.57)	0.75	1.59(1.09-2.32)	0.02	0.15
VDR:rs12721364(G,A)	1.34(0.89-2.02)	0.16	0.67(0.44-1.02)	0.06	0.05
VDR:rs10875693(T,A)	0.66(0.46-0.96)	0.03	1.16(0.82-1.64)	0.42	0.23
VDR:rs4760648(C,T)	0.85(0.63-1.14)	0.27	1.23(0.90-1.69)	0.19	0.03
GC:rs1155563(T,C)	0.96(0.69-1.33)	0.81	1.54(1.10-2.14)	0.01	0.12
GC:rs1491716(G,A)	0.50(0.25-0.98)	0.04	1.25(0.68-2.30)	0.48	0.70
GC:rs6817912(C,T)	1.93(1.00-3.70)	0.05	0.93(0.48-1.81)	0.83	0.72
GC:rs12640179(C,G)	1.81(0.99-3.31)	0.05	0.72(0.36-1.48)	0.37	0.03
CYP27A1:rs647952(A,G)	0.20(0.05-0.74)	0.02	1.28(0.48-3.41)	0.63	0.51
CYP2R1:rs2060793(G,A)	1.34(1.00-1.79)	0.05	1.13(0.84-1.52)	0.42	0.03
CYP2R1:rs12794714(G,A)	0.69(0.51-0.93)	0.01	0.86(0.63-1.16)	0.32	0.04
CYP2R1:rs1562902(T,C)	1.41(1.04-1.90)	0.03	1.05(0.79-1.42)	0.72	0.004
CYP2R1:rs10832312(T,C)	1.65(1.02-2.65)	0.04	0.88(0.52-1.49)	0.64	0.04
CYP2R1:rs11023374(T,C)	0.75(0.53-1.07)	0.11	0.97(0.68-1.38)	0.85	0.01
CYP24A1:rs2585413(G,A)	0.93(0.67-1.29)	0.67	0.71(0.51-0.98)	0.04	0.48
CYP24A1:rs2585415(G,A)	0.99(0.72-1.35)	0.93	0.70(0.51-0.96)	0.03	0.21
CYP24A1:rs927650(C,T)	0.99(0.73-1.33)	0.94	1.50(1.11-2.04)	0.009	0.19
CYP24A1:rs3787555(C,A)	1.40(1.00-1.96)	0.05	0.81(0.57-1.16)	0.25	0.78
RXRA:rs1536475(G,A)	1.09(0.73-1.61)	0.69	0.79(0.51-1.20)	0.27	0.03

^*Per-minor allele odds ratio for fatal prostate cancer, adjusted for age at diagnosis

^#Wald p-value for SNP coded (0,1,2)*25(OH)D (continuous); 25(OH)D was standardized by cohort, season, and laboratory assay batch.